JPWO2021080950A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021080950A5
JPWO2021080950A5 JP2022523522A JP2022523522A JPWO2021080950A5 JP WO2021080950 A5 JPWO2021080950 A5 JP WO2021080950A5 JP 2022523522 A JP2022523522 A JP 2022523522A JP 2022523522 A JP2022523522 A JP 2022523522A JP WO2021080950 A5 JPWO2021080950 A5 JP WO2021080950A5
Authority
JP
Japan
Prior art keywords
biomarker
level
sample
protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552883A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056431 external-priority patent/WO2021080950A1/en
Publication of JP2022552883A publication Critical patent/JP2022552883A/ja
Publication of JPWO2021080950A5 publication Critical patent/JPWO2021080950A5/ja
Pending legal-status Critical Current

Links

JP2022523522A 2019-10-21 2020-10-20 血液がんの治療方法ならびに2-(2,6-ジオキソピペリジン-3-イル)-4-((2-フルオロ-4-((3-モルホリノアゼチジン-1-イル)メチル)ベンジル)アミノ)イソインドリン-1,3-ジオンに対するコンパニオンバイオマーカーの使用 Pending JP2022552883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924044P 2019-10-21 2019-10-21
US62/924,044 2019-10-21
PCT/US2020/056431 WO2021080950A1 (en) 2019-10-21 2020-10-20 Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (2)

Publication Number Publication Date
JP2022552883A JP2022552883A (ja) 2022-12-20
JPWO2021080950A5 true JPWO2021080950A5 (pt) 2023-12-08

Family

ID=75490827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523522A Pending JP2022552883A (ja) 2019-10-21 2020-10-20 血液がんの治療方法ならびに2-(2,6-ジオキソピペリジン-3-イル)-4-((2-フルオロ-4-((3-モルホリノアゼチジン-1-イル)メチル)ベンジル)アミノ)イソインドリン-1,3-ジオンに対するコンパニオンバイオマーカーの使用

Country Status (11)

Country Link
US (1) US20210116454A1 (pt)
EP (1) EP4048668A4 (pt)
JP (1) JP2022552883A (pt)
KR (1) KR20220103949A (pt)
CN (1) CN115175903A (pt)
AU (1) AU2020372333A1 (pt)
BR (1) BR112022007386A2 (pt)
CA (1) CA3154890A1 (pt)
IL (1) IL292305A (pt)
MX (1) MX2022004688A (pt)
WO (1) WO2021080950A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202415665A (zh) 2022-06-06 2024-04-16 美商樹線生物科學公司 三環喹啉酮bcl6雙功能降解劑
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
CN115261469B (zh) * 2022-06-23 2023-03-31 山东第一医科大学附属省立医院(山东省立医院) Brd9在慢性淋巴细胞白血病诊治中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200901852B (en) * 2006-09-15 2010-06-30 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
CA2834535A1 (en) * 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2867671B1 (en) * 2012-06-29 2018-10-24 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
CN118547067A (zh) * 2013-03-15 2024-08-27 豪夫迈·罗氏有限公司 治疗pd-1和pd-l1相关疾患的生物标志物和方法
BR112016012792A2 (pt) * 2013-12-06 2017-08-08 Celgene Corp Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras
JP7001614B2 (ja) * 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
US20200054639A1 (en) * 2016-10-31 2020-02-20 Oregon Health & Science University Combinations of agents to treat hematological malignancies
DK3784663T3 (da) * 2018-04-23 2023-10-16 Celgene Corp Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Similar Documents

Publication Publication Date Title
Tew et al. Association between response to etrolizumab and expression of integrin αE and granzyme A in colon biopsies of patients with ulcerative colitis
Grandis et al. Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell lines
US11579140B2 (en) Methods related to bronchial premalignant lesion severity and progression
EP3325661B1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
Guenterberg et al. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis
WO2018184003A1 (en) Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
Lee et al. Gene expression profile in interleukin-4-stimulated human vascular endothelial cells
JP2005512961A5 (pt)
US20210116454A1 (en) Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
KR20180026215A (ko) 방사선 피폭 진단용 조성물 및 이를 이용한 방사선 피폭 진단방법
Srivastava et al. Age and gender related differences in human parotid gland gene expression
Vergara et al. Genetic drivers of non‐cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape
Pettiette et al. MicroRNA expression profiles in external cervical resorption
Li et al. Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
WO2016201365A2 (en) Methods for treating cancers
Hinshaw et al. Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer
Thomas et al. Single-cell RNA-seq reveals intratumoral heterogeneity in osteosarcoma patients: A review
JPWO2021080950A5 (pt)
EP2904108B1 (en) Methods for predicting multiple myeloma treatment response
WO2015157247A1 (en) Compositions and methods related to dormant senescence-prone cells (dspc)
US20220242955A1 (en) Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
Drieux et al. How molecular advances may improve the diagnosis and management of PTCL patients
ES2971091T3 (es) Un método para supervisar las respuestas farmacodinámicas mediadas por la administración de glucocorticoides in vivo
Zimmerer et al. IFN-α-2b–Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m2
Alawadi Interleukin-6 level among Iraqi patients with chronic lymphocytic leukemia from Babil Province